Amgen Investors Increase Stakes as Tezspire Phase 3 Endpoints Met
Brighton Jones LLC boosted its Amgen holdings by 23.5% in the fourth quarter, while Sivia Capital Partners raised its stake by 10.6% in the second quarter and Ieq Capital LLC increased its position by 5.1% in the second quarter. Analysts adjusted Amgen price targets. Amgen and AstraZeneca reported Tezspire met co-primary and key secondary endpoints in Phase 3 CROSSING for eosinophilic esophagitis.